We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Fastnet Equity | LSE:FAST | London | Ordinary Share | GB00B85HRF56 | ORD 3.8P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 2.975 | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMFAST
RNS Number : 5212V
Fastnet Equity PLC
18 April 2016
Fastnet Equity plc
("Fastnet" or the "Company")
Result of General Meeting and Change of Name
18 April 2016, London - Further to the announcement on 31 March 2016 in relation to the Proposals, the Directors are pleased to announce that all resolutions proposed at the General Meeting of the Company held earlier today were approved. Consequently the Acquisition will now proceed and accordingly the Company's name will change to Amryt Pharma plc ("Amryt"). Following the change of name, the Company's ticker will change to 'AMYT' on AIM and 'AYP' on the ESM.
Following the Capital Reorganisation, the Company's ISIN and SEDOL will change to GB00BDD1LS57 and BDD1LS5, respectively. It is expected that the New Ordinary Shares arising as a result of the Capital Reorganisation in respect of Existing Ordinary Shares held in uncertificated form, i.e. in CREST, will be credited to the relevant CREST accounts on 19 April 2016.
Trading on AIM and the ESM of the Existing Ordinary Shares of the Company will be cancelled, and re-admission and dealings in New Ordinary Shares in Amryt will commence on AIM and ESM, at 8.00 a.m. on 19 April 2016.
Terms used in this announcement shall have the meanings given to them in the Company's admission document dated 31 March 2016.
The Admission Document is available on the Company's website www.amrytpharma.com
For further information, please contact:
Amryt Pharma plc C/o FTI Consulting Joe Wiley, CEO Rory Nealon, CFO/COO +44 (0) 20 Shore Capital 7408 4090 Nomad and Joint Broker Bidhi Bhoma, Edward Mansfield +353 (1) 679 Davy 6363 ESM Adviser and Joint Broker John Frain, Anthony Farrell +44 (0) 20 Stifel 7710 7600 Joint Broker Jonathan Senior, Ben Maddison +44 (0) 20 FTI Consulting 3727 1000 Simon Conway, Brett Pollard
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCAKFDKDBKDNQD
(END) Dow Jones Newswires
April 18, 2016 07:41 ET (11:41 GMT)
1 Year Fastnet Equity Chart |
1 Month Fastnet Equity Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions